title: Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?
abstract: OBJECTIVE
  To evaluate the effect of body mass index (BMI) on the histopathological and clinical outcome in prostate cancer.
  
  
  METHODS
  In a prospective urological cancer database, 620 patients with prostate cancer had a radical prostatectomy (RP) as a curative treatment. The patients were categorized into three groups of BMI (kg/m(2)); <or=25.0 (190, 'normal weight'), >25.0-30.0 (343, 'overweight') and >30.0 (87, 'obese'). We evaluated the histopathological features and the clinical follow-up after RP. The median (range) age of the men was 64.4 (41.1-80.1) years and the median follow-up 5.5 (0.1-15.1) years. The preoperative median prostate-specific antigen (PSA) levels for normal, overweight and obese patients were 9.0 (0.3-133.0), 8.9 (0.4-230.0) and 9.2 (0.5-194.0) ng/mL, respectively.
  
  
  RESULTS
  Serum PSA levels were no different among the three groups (P = 0.92). The normal, overweight and obese patients had organ-confined prostate cancer in 53.7%, 57.1% and 58.6%, respectively (P = 0.34) and had lymph node metastases in 7.9%, 7.6% and 4.6% (P = 0.58). Tumour grading was no different for the three groups (P = 0.25). The PSA recurrence-free, prostate cancer-specific and overall survival for the three BMI groups did not differ significantly (each P > 0.05).
  
  
  CONCLUSIONS
  The BMI cannot be shown to be a predictor of adverse prognosis either for histopathological features or for the clinical outcome, e.g. PSA-free, prostate cancer-specific and overall survival, in a mid-European study population after RP.
authors.affiliation: Department of Urology, Medical Centre, University of Heidelberg, Heidelberg, Germany. jesco.pfitzenmaier@med.uni-heidelberg.de
authors.forename: Jesco
authors.initials: J
authors.lastname: Pfitzenmaier
authors.forename: Maria
authors.initials: M
authors.lastname: Pritsch
authors.forename: Axel
authors.initials: A
authors.lastname: Haferkamp
authors.forename: Hildegard
authors.initials: H
authors.lastname: Jakobi
authors.forename: Frederik
authors.initials: F
authors.lastname: Fritsch
authors.forename: Christian
authors.initials: C
authors.lastname: Gilfrich
authors.forename: Nenad
authors.initials: N
authors.lastname: Djakovic
authors.forename: Stephan
authors.initials: S
authors.lastname: Buse
authors.forename: Sascha
authors.initials: S
authors.lastname: Pahernik
authors.forename: Markus
authors.initials: M
authors.lastname: Hohenfellner
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D050177:Overweight / Q000150:complications*; D011379:Prognosis; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000150:complications / Q000473:pathology* / Q000601:surgery; D012307:Risk Factors; D012720:Severity of Illness Index; D016019:Survival Analysis
chemical_list: D017430:Prostate-Specific Antigen